Physician profile
Caleb T Chu
NPI 1316668320
$1,169.87
in general payments reported to CMS, 2019-2025
11 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $277 · 2024: $259 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $277.42 | 2023 | Nuplazid |
| Novo Nordisk INC | $189.92 | 2024-2025 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $166.42 | 2024-2025 | Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $139.34 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $120.27 | 2024-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $115.22 | 2024-2025 | |
| Insmed, INC. | $50.99 | 2025 | Arikayce |
| Alnylam Pharmaceuticals INC. | $33.75 | 2025 | Amvuttra |
| Amgen INC. | $29.87 | 2025 | Krystexxa |
| Lundbeck LLC | $28.20 | 2025 | Rexulti |
| Lilly USA, LLC | $18.47 | 2025 | Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.